High BTK expression was associated with reduced overall survival in a cohort of 50 ovarian cancer patients and the combination of cisplatin and ibrutinib demonstrated synergy in two ovarian cancer cell lines19. This evidence concerns the gene BTK and ovarian carcinoma.